Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy
Reported: September 10, 2025 Initiated: July 9, 2025 #D-0609-2025
Product Description
Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy
Reason for Recall
Subpotent Drug
Details
- Recalling Firm
- Boothwyn Pharmacy LLC
- Units Affected
- 648 vials
- Distribution
- U.S. Nationwide
- Location
- Kennett Square, PA
Frequently Asked Questions
What product was recalled? ▼
Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy. Recalled by Boothwyn Pharmacy LLC. Units affected: 648 vials.
Why was this product recalled? ▼
Subpotent Drug
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on September 10, 2025. Severity: Moderate. Recall number: D-0609-2025.
Related Recalls
FDA Drug Moderate
Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: U…
Unichem Pharmaceuticals USA Inc. · 2026-02-11
FDA Drug Critical
Green Lumber Natural Fuel For Men capsule, packaged in 2, 4, 10, and 30-count blister packs. GreenLumber.com, 2618 San…
Green Lumber Holdings, LLC · 2026-02-11
FDA Drug Moderate
Trazodone Hydrochloride, USP, 50 mg, 100-Count Bottle, Rx only, Manufactured by: Granules India Limited, Hyderabad, 500…
Granules Pharmaceuticals Inc. · 2026-02-11
FDA Drug Critical
Diclofenac Sodium, Topical Gel, 3%, 100 g, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1…
SUN PHARMACEUTICAL INDUSTRIES INC · 2026-02-11
FDA Drug Critical
Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt. Ltd., Ahmedabad, India UPC 8 904218 700313
HANDELNINE GLOBAL LLC · 2026-02-11